Sanofi (SNYNF, SNY) has announced the shipment of BEYFORTUS 50mg and 100mg injection doses to private healthcare providers in the United States, as well as to the Centers for Disease Control and Prevention for inclusion in its Vaccines for Children program.
BEYFORTUS is the first and only long-acting monoclonal antibody approved for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants born during or entering their first RSV season. It is also approved for children up to 24 months of age who continue to be at risk for severe RSV disease during their second RSV season.
